A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma

BACKGROUND: Bevacizumab has promising activity against recurrent glioblastoma (GBM). However, acquired resistance to this agent results in tumor recurrence. We hypothesized that vorinostat, a histone deacetylase (HDAC) inhibitor with anti-angiogenic effects, would prevent acquired resistance to beva...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Puduvalli, Vinay K, Wu, Jing, Yuan, Ying, Armstrong, Terri S, Vera, Elizabeth, Wu, Jimin, Xu, Jihong, Giglio, Pierre, Colman, Howard, Walbert, Tobias, Raizer, Jeffrey, Groves, Morris D, Tran, David, Iwamoto, Fabio, Avgeropoulos, Nicholas, Paleologos, Nina, Fink, Karen, Peereboom, David, Chamberlain, Marc, Merrell, Ryan, Penas Prado, Marta, Yung, W K Alfred, Gilbert, Mark R
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7686463/
https://ncbi.nlm.nih.gov/pubmed/32166308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa062
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires